« Return to News | Drug Sponsors

Orexo focuses its business and reduces costs

Friday, March 16, 2012 12:10 PM

Uppsala, Sweden-based Orexo is focusing its development activities to the three proprietary programs OX219, OX51 and OX27, cutting 35 full-time employees in the process.

The personnel reduction, which will be completed during Q2 of 2012, is expected to lower the costs by a total of $4.4 million annually. Negotiations with trade union representatives will commence immediately.

"The focus of our business activities will now be fully in line with Orexo's strategy and we shall exclusively invest in further development and commercialization of our proprietary products,” said Anders Lundström, CEO, Orexo. “This means that we are directing all our resources towards our key later stage development programs.

The three programs, OX219, OX51 and OX27, are based on proprietary drug delivery technologies applied to well-known substances with licensed uses. This results in programs with significantly lower development risk, lower cost and shorter development time than traditional drug development programs. This approach was used to successfully develop Orexo's pain product Abstral and the insomnia product Edluar.

Today, Orexo has 110 employees, of which approximately 80 work in R&D.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.